Despite Steep Costs, Payments for New Cancer Drugs Make Economic Sense

Full text for this resource is not available from the Research Repository.

Lichtenberg, Frank R (2011) Despite Steep Costs, Payments for New Cancer Drugs Make Economic Sense. Nature Medicine, 17 (3). p. 244. ISSN 1078-8956

Abstract

Cancer drugs have become more expensive over the past few years, leading many people to question whether the treatments are really worth their high costs. But despite the sticker shock, cancer medicines have provided good value for money.

Item type Article
URI https://vuir.vu.edu.au/id/eprint/9443
Official URL http://www.nature.com/nm/journal/v17/n3/pdf/nm0311...
Subjects Historical > FOR Classification > 1112 Oncology and Carcinogenesis
Historical > FOR Classification > 1402 Applied Economics
Historical > SEO Classification > 970114 Expanding Knowledge in Economics
Historical > Faculty/School/Research Centre/Department > Centre for Strategic Economic Studies (CSES)
Keywords ResPubID24425, Avastin, Rituxan, Gleevec, Herceptin, cancer therapy, survival rate
Citations in Scopus 8 - View on Scopus
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login